跳至主要内容
临床试验/NCT06429579
NCT06429579招募中不适用

Multicenter, Prospective, and Exploratory Study of Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension

China National Center for Cardiovascular Diseases1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2024年4月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
120
试验地点
1
主要终点
Mortality or Lung transplantation

研究概览

简要总结

This is a multi-center, perspective, and exploratory study aimed at evaluating the 3-years clinical outcome of Potts-shunt procedure for pediatric patients with severe pulmonary artery hypertension (PAH). The included criteria are as followed: 1)6 months < age ≤ 18 years; 2) ESC 2022 Group I PAH; 3) Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022; 4) Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc); 5) Informed consent form signed by the patient and their guardian. The excluded criteria are as followed: 1) ESC 2022 Group II-V PAH; 2) Poor right ventricular function: RVEF < 25% or RVFAC < 20%; 3) Deteriorated general condition: requiring ICU resuscitation or ECMO assistance; 4) Pulmonary artery pressure/main arterial pressure ratio < 0.7; 5) Six-minute walk distance < 150 meters (only applicable to patients aged 8 and above); 6) No significant improvement in RVEF under triple drug therapy. All of the pediatric patients with severe PAH who attend to pediatric cardiac outpatient clinic and meet the designed included criteria and excluded criteria will be enrolled in this study. All of the participants will be divided into two groups (Potts-shunt combined with conventional drug therapy group and only conventional drug therapy group) according to their individual health status (i.e., some contraindications of surgery) and their (or their parents') aspiration for Potts-shunts procedure. Follow-up is designed (eight-times follow-up) at the time of Potts-shunt procedure, post-operative ICU period, one month, three months, six months, one year, two years, and three years after Potts-shunt procedure or the rejection of Potts-shunt procedure. The items of follow-up include state of survival, whether or not have the lung transplantation (LTx), clinical manifestation, laboratory examination, function of right ventricle (detected by echocardiogram and cardiac magnetic resonance imaging), and the pulmonary circulation pressure (detected by right heart catheterization or Swan-Ganz catheterization). Primary outcome is the incidence rates of death or LTx three-years after Potts-shunt. Secondary outcomes are as followed: 1) Number and incidence rate of postoperative complications in patients undergoing Potts-shunt procedure; 2) Three-year WHO cardiac functional and 6-minute walk distance after Potts-shunt procedure; 3) the NT-ProBNP levels three-years after Potts-shunt procedure; 4) Right ventricular function on echocardiography three years after Potts-shunt procedure; 5) Right ventricular function on cardiac magnetic resonance imaging three years after Potts-shunt procedure; 6) Pulmonary circulation pressure measured by right heart catheterization or Swan-Ganz catheterization three years after Potts-shunt procedure; 7) Three-year mortality or LTx incidence rates after only conventional drug therapy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 6 months &lt; age ≤ 18 years;
  • ESC 2022 Group I PAH;
  • Have received standardized drug therapy for at least 6-9 months and still remain at intermediate to high/high-risk status of the criteria of ESC2022;
  • Presenting with significant clinical manifestations (i.e., progressive symptoms/syncope history/growth and development restriction, etc);
  • Informed consent form signed by the patient and their guardian.

排除标准

  • ESC 2022 Group II-V PAH;
  • Poor right ventricular function: RVEF &lt; 25% or RVFAC &lt; 20%;
  • Deteriorated general condition: requiring ICU resuscitation or ECMO assistance;
  • Pulmonary artery pressure/main arterial pressure ratio &lt; 0.7;
  • Six-minute walk distance &lt; 150 meters (only applicable to patients aged 8 and above);
  • No significant improvement in RVEF under triple drug therapy.

研究组 & 干预措施

Potts-shunt combined with conventional drug therapy group

Experimental

The comprehensive therapy included Potts-shunt procedure and conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)

干预措施: Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy (Procedure)

Only conventional drug therapy group

Active Comparator

Only admitted with conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)

干预措施: Only conventional drug therapy (Drug)

结局指标

主要结局

Mortality or Lung transplantation

时间窗: From the date of enrollment until the date of dear from any cause or lung transplantation, which ever came first, accessed up to 3 years

The incidence rates of death or lung transplantation 3 years after Potts-shunt, accessed by in-patient, out-patient, or telephone follow-up

次要结局

  • NT-ProBNP levels after Potts-shunt procedure(From the date of enrollment to the date of every view-point, assessed up to 3 years)
  • The 6-minutes distance after Potts-shunt procedure(From the date of enrollment to the date of every view-point, assessed up to 3 years)
  • Number and incidence rate of postoperative complications in patients undergoing Potts-shunt procedure(From the date of enrollment to the date of any postoperative complications, whichever came first, accessed up to 3 years)
  • Right ventricular function on echocardiography after Potts-shunt procedure(From the date of enrollment to the date of every view-point, assessed up to 3 years)
  • Pulmonary circulation pressure measured by right heart catheterization or Swan-Ganz catheterization after Potts-shunt procedure(From the date of enrollment to the date of every view-point, assessed up to 3 years)
  • Mortality or lung transplantation incidence rates after only conventional drug therapy(From the date of enrollment until the date of dear from any cause or lung transplantation, which ever came first, accessed up to 3 years)
  • World Health Organization functional class (WHO-FC) after Potts-shunt procedure(From the date of enrollment to the date of every view-point, assessed up to 3 years)
  • Right ventricular function on cardiac magnetic resonance imaging after Potts-shunt procedure(From the date of enrollment to the date of every view-point, assessed up to 3 years)

研究者

发起方
China National Center for Cardiovascular Diseases
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Potts-shunt for the Treatment of Pediatric Patients... | 临床试验